Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study

Draaisma, Kaspar, Chatzipli, Aikaterini, Taphoorn, Martin, Kerkhof, Melissa, Weyerbrock, Astrid, Sanson, Marc, Hoeben, Ann, Lukacova, Slavka, Lombardi, Giuseppe, Leenstra, Sieger, Hanse, Monique, Fleischeuer, Ruth, Watts, Colin, McAbee, Joseph, Angelopoulos, Nicos ORCID: https://orcid.org/0000-0002-7507-9177, Gorlia, Thierry, Golfinopoulos, Vassilis, Kros, Johan M., Verhaak, Roel G. W., Bours, Vincent, van den Bent, Martin J., McDermott, Ultan, Robe, Pierre A. and French, Pim J. 2020. Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study. Journal of Clinical Oncology 38 (1) , pp. 81-99. 10.1200/JCO.19.00367

Full text not available from this repository.

Abstract

PURPOSE Precision medicine trials in glioblastoma (GBM) are often conducted at tumor recurrence. However, second surgeries for recurrent GBM are not routinely performed, and therefore, molecular data for trial inclusion are predominantly derived from the primary sample. This study aims to establish whether molecular targets change during tumor progression and, if so, whether this affects precision medicine trial design. MATERIALS AND METHODS We collected 186 pairs of primary-recurrent GBM samples from patients receiving chemoradiotherapy with temozolomide and sequenced approximately 300 cancer genes. MGMT, TERT, and EGFRvIII status was individually determined. RESULTS The molecular profile of our cohort was identical to that of other GBM cohorts (IDH wild-type [WT], 95%; EGFR amplified, approximately 50%), indicating that patients amenable to second surgery do not represent a specific molecular subtype. Molecular events in IDH WT GBMs were stable in approximately 80% of events, but changes in mutation status were observed for all examined genes (range, approximately 90% and 60% for TERT and EGFR mutations, respectively), and such changes strongly affected targeted trial size and design. A similar pattern of GBM driver instability was observed within MGMT promoter–methylated tumors. MGMT promoter methylation status remained prognostic at tumor recurrence. The observation that hypermutation at GBM recurrence was rare (8%) and not correlated with outcome was relevant for immunotherapy-based treatments. CONCLUSION This large cohort of matched primary and recurrent IDH WT tumors establishes the frequency of GBM driver instability after chemoradiotherapy with temozolomide. This allows per gene or pathway calculation of trial size at tumor recurrence, using molecular data of the primary tumor only. We also identify genes for which repeat surgery is necessary because of low mutation retention rate.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Date of Acceptance:	7 August 2019
Last Modified:	04 Jan 2023 02:19
URI:	https://orca.cardiff.ac.uk/id/eprint/133796

Citation Data

Cited 52 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item